Newswise — Enzo is pleased to announce the launch of a new primary antibody validated for IHC, our p16INK4a monoclonal antibody. Our antibody is specific to the p16INK4A protein, a cyclin-dependent kinase inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma (Rb) protein, p16 decelerates cellular differentiation and acts as a tumor suppressor. It is the key marker in several human cancers including cervical cancer, head and neck cancers, perianal lesions, melanomas, gliomas, and lymphomas. Our p16INK4A antibody is designed to deliver minimal background and outstanding staining quality when paired with our POLYVIEW® PLUS IHC Detection Reagents.

Our p16 antibody provides equivalent signal to our major competitor at a much more affordable price. At a time when reagents are becoming more and more expensive, Enzo continues to be a provider of low-cost, highly effective and easily adaptable solutions to the market. Our p16 antibody is the latest addition to our growing portfolio of over 1,000 IHC-validated antibodies.

About Enzo

Enzo Biochem is an integrated diagnostics company, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. Enzo Biochem is a pioneer in labeling and detection technologies with over 40 years of experience in the field. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Enzo Life Sciences, Inc. is a pioneer in labeling and detection technologies from genome to whole cell across research and diagnostic markets. We are focused on providing cost-effective, relevant and reliable solutions for life science research, drug development, and clinical research. We are organized to lead in the development, production, marketing, and sales of innovative research tools worldwide based on 40 years’ experience in building strong global market recognition and implementing outstanding operational capabilities.

CONTACT

Kara Cannon, Global Head of Marketing
1-631.694.7070 x 1301

KCannon@enzolifesciences.com